液体活检在直肠癌新辅助治疗中的研究进展  

Research progress of liquid biopsy in the neoadjuvant treatment of rectal cancer

作　　者：赵韵琳 黄诗 柯舒慧 林丹丹[1] ZHAO Yunlin;HUANG Shi;KE Shuhui;LIN Dandan(Cancer Center,Renmin Hospital of Wuhan University,Hubei Province,Wuhan430060,China)

机构地区：[1]武汉大学人民医院肿瘤中心,湖北武汉430060

出　　处：《中国医药导报》2023年第30期55-58,共4页China Medical Herald

基　　金：国家自然科学基金面上项目(32270951)。

摘　　要：液体活检是一项新兴的检测技术,具有创伤小、特异性高、避免肿瘤异质性等优势,在肿瘤的早筛、疗效评估、复发监测中均有应用。对于接受新辅助治疗的中低位局部晚期直肠癌(LARC)患者,判断新辅助治疗的效果及监测肿瘤的复发决定了治疗方案的选择。多项研究证实液体活检能预测LARC患者新辅助治疗效果,且较肿瘤标志物CEA及影像学提前监测到肿瘤复发,以及能预估患者长期生存预后,从而为接受新辅助治疗的LARC提供更个性化的治疗策略。本文围绕液体活检中的几项指标,回顾与总结液体活检在新辅助治疗LARC中的应用。Liquid biopsy is an emerging detection technique with the advantages of being less invasive,highly specific,and avoiding tumor heterogeneity and it used in early screening,efficacy assessment,and recurrence monitoring of tumors.For patients with low to intermediate locally advanced rectal cancer(LARC)receiving neoadjuvant therapy,determining the efficacy of neoadjuvant therapy and monitoring tumor recurrence determines treatment options.Several studies demonstrate that liquid biopsy can predict the effectiveness of neoadjuvant treatment in patients with LARC,monitor tumor recurrence earlier than tumor markers such as carcinoembryonic antigen and imaging,and show the long-term survival prognosis of patients,thus providing a more personalized treatment strategy for patients with LARC receiving neoadjuvant therapy.This article reviews and summarizes the use of liquid biopsy in the neoadjuvant treatment of LARC,focusing on several indicators in liquid biopsy.

关 键 词：液体活检 直肠癌 新辅助治疗 生物技术 

分 类 号：R735.34[医药卫生—肿瘤]